Dimerix (ASX: DXB) has announced the appointment of Dr Ash Soman as chief medical officer and a member of its executive management team.
The company said Dr Soman will lead its multiple global clinical development programs and medical affairs.
Dr Soman has over 30 years of experience across hospital clinical practice, clinical study design, medical affairs, compliance, patient safety and corporate strategy.
Most recently, Dr Soman was the medical director for the global IQVIA, where he managed strategy, early-phase clinical trial design, development and oversight for emerging biotechnology companies in multiple therapy areas, including COVID-19.
He previously held roles with AstraZeneca, Sanofi-Aventis Australia-New Zealand, Oncosil Medical and Roche.
“I am delighted to be joining the team at Dimerix at an exciting time. I believe that Dimerix has the potential to deliver substantial value to patients with both chronic renal and respiratory diseases moving forward, as well as our employees, investors and the wider community," said Dr Soman.